Finally! 3 Figures From Valeant's Second-Quarter Report That Demonstrate Improvement
If you've ever played the board game Chutes and Ladders and landed on space 87, which throws the player back 63 spaces, you might have some idea of what it's been like to be a Valeant Pharmaceuticals (NYSE: VRX) shareholder over the past two years. The only difference is that Valeant has hit this proverbial chute on space 87 that's sent it screaming backward over and over again.
Shares of the embattled drugmaker are down well over 90%, and more than $80 billion in market cap, since their peak in August 2015. What was once a company that thrived from increasing the price of its drugs, and boosted growth via debt-financed acquisitions, is now struggling to pass along inflation-topping price increases and has had its merger-and-acquisition growth engine come to a grinding halt.
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Stock
Currently there is a rather positive sentiment for Bausch Health Companies Inc. with 3 Buy predictions and 0 Sell predictions.
Based on the current price of 6.22 € the target price of 16 € shows a potential of 157.15% for Bausch Health Companies Inc. which would more than double the current price.
